fbpx All | Page 37 | Science in the net

All

A tour through European scientific governance

European research is fundamental for guaranteeing future competitiveness to our economies, as acknowledged by all EU member States that committed to reach investments in research and development equal to 3% of GDP. Up to date, however, the funds allocated by the 28 Countries of the Union remain below the 2% of GDP and on average do not exceed 0.7% (Fig. 1). Some Nations, however, are reversing their route. In 2000, Germany and France presented similar balance sheets; ten years later, Germany remains the only country that constantly increased public funds.

An overview on the global response to the 2009 H1N1 pandemic

In a review on the New England Journal of Medicine, Harvey Fineberg, president of the Institute of Medicine and chair of an international committee requested by the World Health Organization (WHO), analyzed the global response to the 2009 H1N1 pandemic, giving particular attention to the function of the 2005 International Health Regulations (IHR) and the performance of the WHO.

Brainstorming the research: the future of brain studies

One of the most unknown places, still far from being explored and fully understood, is not (only) the deep universe: it is our brain. That is why USA and the European Union, in the very last years, started two separate, but parallel, initiatives to map the human brain. On March 2014, there has been a public announcement that the two projects will merge. Or will they smash?

The Human Brain Project

EU funding for robotics research

Nowadays, over two-thirds of European workers in manufacturing are employed in small and medium-sized enterprises (SMEs). This is a considerable percentage that UE must consider in its decision concerning funding for Research and Development. One of the most significant aim of SMEs is to offer a valid answer to changing production needs that are developing more and more quickly in our contemporary society, and robotics represents in this sense one of the major challenges.

Cochrane and BMJ questioned Tamiflu and Relenza effectivenes

There is no good evidence about the effectiveness of Tamiflu (oseltamivir) and Relenza (zanamivir) for influenza prevention and treatment. This is the though claim made by Cochrane Collaboration and the British Medical Journal (BMJ), based on the extended systematic review they just published about the use of neuraminidase inhibitors against influenza.